Litcius/Paper detail

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions

Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, Ashraf N. Abdalla, Bahaa G. M. Youssif, Nashwa A. Ibrahim, Mohammed Gamal, Hany A.M. El-Sherief, Maha M. Abdel‐Fattah, Ahmed A. Hefny, Ahmed H. Abdelazeem, Ahmed M. Gouda

2024European Journal of Medicinal Chemistry20 citationsDOIOpen Access PDF

Topics & Concepts

ChemistrySmall moleculeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)StereochemistryCovalent bondMoleculeBiological activityCombinatorial chemistryCoronavirus disease 2019 (COVID-19)Computational biologyBiochemistryIn vitroOrganic chemistryInfectious disease (medical specialty)PathologyBiologyMedicineDiseaseComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchSynthesis and biological activity
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions | Litcius